Loading clinical trials...
Loading clinical trials...
A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Crinecerfont in Pediatric Participants 3 Months to <4 Years of Age With Classic Congenital Adrenal Hyperplasia
Conditions
Interventions
Crinecerfont
Start Date
April 1, 2026
Primary Completion Date
March 1, 2028
Completion Date
March 1, 2028
Last Updated
April 17, 2026
NCT06573723
NCT06712823
NCT03760835
NCT04463316
NCT05907291
NCT06449456
Lead Sponsor
Neurocrine Biosciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions